Dublin medical device company Mainstay hopes to launch back pain product this year

Irish medical device company Mainstay Medical has identified Germany as the launch market, later this year, for its breakthrough treatment for chronic back pain.

The Dublin company is awaiting the European CE Mark — a sign that a product meets regulatory requirements — for its ReActiv8 device but expects to receive it this year ahead of a roll-out in Germany and other markets.

Mainstay is also due to commence clinical trials for the product in the US in the coming months before hopefully going to market there in 2017 or 2018.